Zhuhai Sailong Pharmaceutical Co Ltd (002898) - Total Liabilities

Latest as of March 2026: CN¥477.34 Million CNY ≈ $69.85 Million USD

Based on the latest financial reports, Zhuhai Sailong Pharmaceutical Co Ltd (002898) has total liabilities worth CN¥477.34 Million CNY (≈ $69.85 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Zhuhai Sailong Pharmaceutical Co Ltd - Total Liabilities Trend (2013–2025)

This chart illustrates how Zhuhai Sailong Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See 002898 current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.

Zhuhai Sailong Pharmaceutical Co Ltd Competitors by Total Liabilities

The table below lists competitors of Zhuhai Sailong Pharmaceutical Co Ltd ranked by their total liabilities.

Company Country Total Liabilities
HansBiomed Corporation
KQ:042520
Korea ₩92.52 Billion
Neto M.E Holdings Ltd
TA:NTO
Israel ILA1.21 Billion
SmartRent Inc
NYSE:SMRT
USA $101.39 Million
ButOne Information Corp XiAn
SHG:600455
China CN¥904.49 Million
Auden Techno
TW:3138
Taiwan NT$1.56 Billion
Dream Office Real Estate Investment Trust
TO:D-UN
Canada CA$1.35 Billion
Azkoyen
MC:AZK
Spain €71.89 Million
Panca Budi Idaman Tbk PT
JK:PBID
Indonesia Rp591.61 Billion

Liability Composition Analysis (2013–2025)

This chart breaks down Zhuhai Sailong Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of Zhuhai Sailong Pharmaceutical Co Ltd.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 0.85 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 1.28 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.56 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Zhuhai Sailong Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Zhuhai Sailong Pharmaceutical Co Ltd (2013–2025)

The table below shows the annual total liabilities of Zhuhai Sailong Pharmaceutical Co Ltd from 2013 to 2025.

Year Total Liabilities Change
2025-12-31 CN¥447.95 Million
≈ $65.55 Million
+44.99%
2024-12-31 CN¥308.95 Million
≈ $45.21 Million
+11.15%
2023-12-31 CN¥277.96 Million
≈ $40.67 Million
-13.58%
2022-12-31 CN¥321.64 Million
≈ $47.07 Million
+0.79%
2021-12-31 CN¥319.12 Million
≈ $46.70 Million
+40.61%
2020-12-31 CN¥226.96 Million
≈ $33.21 Million
+28.26%
2019-12-31 CN¥176.95 Million
≈ $25.89 Million
+91.71%
2018-12-31 CN¥92.30 Million
≈ $13.51 Million
-4.35%
2017-12-31 CN¥96.50 Million
≈ $14.12 Million
+88.43%
2016-12-31 CN¥51.21 Million
≈ $7.49 Million
-0.63%
2015-12-31 CN¥51.53 Million
≈ $7.54 Million
+5.32%
2014-12-31 CN¥48.93 Million
≈ $7.16 Million
-34.27%
2013-12-31 CN¥74.44 Million
≈ $10.89 Million
--

About Zhuhai Sailong Pharmaceutical Co Ltd

SHE:002898 China Biotechnology
Market Cap
$213.76 Million
CN¥1.46 Billion CNY
Market Cap Rank
#16386 Global
#4630 in China
Share Price
CN¥8.30
Change (1 day)
-5.03%
52-Week Range
CN¥8.30 - CN¥16.81
All Time High
CN¥29.47
About

Sailong Pharmaceutical Group Co.,Ltd. researches, develops, produces, markets, and services pharmaceutical intermediates, raw materials, and preparations in China. The company offers esomeprazole sodium, ornithine aspartate, thymus, argatroban, tigecycline, monosialotetrahexose ganglioside sodium, cerebroprotein hydrolysate, milrinone, parecoxib sodium, tranexamic acid, clindamycin phosphate, pan… Read more